866-997-4948(US-Canada Toll Free)

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 34 Pages

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

Summary

Global Markets Directs, DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016, provides in depth analysis on DNA Gyrase Subunit B (EC 5.99.1.3) targeted pipeline therapeutics.

The report provides comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
- The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
- The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
DNA Gyrase Subunit B (EC 5.99.1.3) Overview 6
Therapeutics Development 7
DNA Gyrase Subunit B (EC 5.99.1.3) - Products under Development by Stage of Development 7
DNA Gyrase Subunit B (EC 5.99.1.3) - Products under Development by Therapy Area 8
DNA Gyrase Subunit B (EC 5.99.1.3) - Products under Development by Indication 9
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Products Glance 10
Early Stage Products 10
Unknown Stage Products 11
DNA Gyrase Subunit B (EC 5.99.1.3) - Products under Development by Companies 12
DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development 19
Abgentis Ltd 19
AstraZeneca Plc 20
Daiichi Sankyo Company Ltd 21
Merck & Co Inc 22
DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles 23
DS-2969 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
GP-4 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule to Inhibit DNA Gyrase Subunit B for Bacterial Infections - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecules to Inhibit DNA GyrB for Tuberculosis - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
VT-12008911 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
VXc-100 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
VXC-486 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
DNA Gyrase Subunit B (EC 5.99.1.3) - Featured News & Press Releases 31
Sep 12, 2012: Trius Therapeutics Reports Preclinical Data On Broad-Spectrum Antibiotics At 52nd Annual ICAAC Meeting 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Comparative Analysis by Unknown Stage Development, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Abgentis Ltd, H2 2016 19
Pipeline by AstraZeneca Plc, H2 2016 20
Pipeline by Daiichi Sankyo Company Ltd, H2 2016 21
Pipeline by Merck & Co Inc, H2 2016 22

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *